Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obrixtamig and Pumitamig with or without Chemotherapy in Extensive-stage Small Cell Lung Cancer
NCT07843940Phase 2Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2026
- Primary completion
- Apr 2030
- Countries
- 10
01
Overview
A Phase 2 trial of obrixtamig, pumitamig in Small Cell Lung Cancer (SCLC), sponsored by Boehringer Ingelheim. Started Oct 2026; status: recruiting.
02
Drugs
obrixtamigpumitamig
03
Conditions
Small Cell Lung Cancer (SCLC)
Beyond the preview
Go deeper on NCT07843940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07843940.